एब्रोसिटिनिब और तंबाकू और धूम्रपान का इंटरैक्शन

Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3) ] .

Patients who are current or past smokers are at additional increased risk.

In this trial, current or past smokers had an additional increased risk of overall malignancies.

Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with CIBINQO, particularly in patients with a known malignancy (other than a successfully treated NMSC), patients who develop a malignancy when on treatment, and patients who are current or past smokers.

A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers.